Urgent Breakthroughs in Alzheimer’s Treatment for CT Man, 61

UPDATE: A Connecticut man pushing for answers received a heartbreaking diagnosis of early onset Alzheimer’s disease, but he has also discovered promising treatment breakthroughs that could change his future. Lee Ross, 61, a dedicated father and attorney, has become a beacon of hope for others facing similar battles.

After struggling with memory issues for over two years, Ross sought help from doctors, rejecting misdiagnoses of anxiety and sleep deprivation. His relentless pursuit of a diagnosis culminated in a confirmation earlier this year after extensive testing. “I just knew that something wasn’t right,” Ross stated, highlighting the urgency of awareness around early Alzheimer’s detection.

Alzheimer’s disease is characterized by the buildup of amyloid plaques in the brain, disrupting neural connections and cognitive functions. The diagnosis forced Ross to retire from his role as legislative director at the state judicial branch, a position that relied heavily on memory and reasoning skills.

Reflecting on his diagnosis, Ross admitted, “All of a sudden I am an Alzheimer’s patient.” However, he quickly learned about groundbreaking treatments, including the drug Leqembi, developed by Eisai in partnership with Biogen. This FDA-approved medication is designed to slow the progression of Alzheimer’s by targeting amyloid buildup in the brain.

“I didn’t hesitate for a second,” Ross said regarding his decision to start the treatment. “It was amazing what researchers are doing.”

Ross, supported by his wife Doreen and their two adult sons, emphasized that the benefits of Leqembi significantly outweigh the risks. He noted that while the medication can cause side effects like headache and dizziness, the potential to slow disease progression is crucial. “The alternative is just not an option,” he stressed.

Kristen Cusato, director of communications for the Alzheimer’s Association Connecticut and Rhode Island Chapter, praised the impact of Leqembi, stating it opens “a whole new world to treat patients.” With an estimated 80,000 people living with Alzheimer’s in Connecticut alone, along with double that number of caregivers, the need for effective treatments is critical.

Ross has also become an advocate for early diagnosis and treatment, urging others to prioritize their brain health. “If I could do something, if I could maybe tell my story a bit, maybe they would think ‘I should get some testing,’” he remarked.

As part of his advocacy, Ross is participating in the Walk to End Alzheimer’s in Greater Hartford on October 19, 2023, where he hopes to raise awareness and funds for research. The event opens at 9 a.m. at Rentschler Field, with a ceremonial garden at 10 a.m.. Registration details can be found at alz.org/walk.

In his journey, Ross has discovered that early intervention can lead to better outcomes. The U.S. POINTER clinical trial has shown that lifestyle changes, including physical activity and improved nutrition, can enhance cognitive function in at-risk older adults.

As Ross continues his treatment, he remains hopeful. “So far, I haven’t really felt very different, but I’m not getting any worse,” he shared, expressing gratitude for the advancements in Alzheimer’s care that were unavailable just five years ago.

For anyone needing support or information on Alzheimer’s, the Alzheimer’s Association offers a 24/7 Helpline at 1-800-272-3900 and encourages early discussions with healthcare providers about cognitive health.

With the urgency surrounding Alzheimer’s awareness and treatment, Lee Ross is not just a patient; he is a driving force for change and a source of inspiration for many.